Skip to content
naulon
Not checkedNot checked for notices yet.

Olmesartan-induced enteropathy

Sofia Moura de Azevedo, Diana Isabel Rocha, Daniela Neto and 1 more

Medicina Clínica Práctica · 2023

doi:10.1016/j.mcpsp.2022.100348 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The association between sprue-like enteropathy and olmesartan is described in recent literature and is an entity that manifests with chronic diarrhea and should be considered in its differential diagnosis. Olmesartan is a commonly used antihypertensive and the recognition of this entity may reduce the overuse of expensive complementary means of diagnosis. We present 2 cases of chronic diarrhea without blood, one with severe metabolic acidemia that motivated intensive care and renal replacement therapy. No evidence of infection, negative stool cultures, anti-transglutaminase was negative. In both cases, there were no macroscopy alterations, and biopsy was performed in one of the cases. It was considered olmesartan-associated enteropathy, and with its suspension, the clinic did not recur. Being a reversible side effect of a common drug, we should consider their suspension before initiating an extensive investigation of chronic diarrhea. Resumen: La asociación entre la enteropatía tipo esprue y el olmesartán está descrita en la literatura reciente y es una entidad que se manifiesta con diarrea crónica y debe ser considerada en su diagnóstico diferencial. El olmesartán es un antihipertensivo de uso común y el reconocimiento de esta entidad puede reducir el uso excesivo de medios complementarios costosos de diagnóstico. Presentamos dos casos de diarrea crónica, uno de ellos con acidemia metabólica grave que motivó cuidados intensivos y terapia renal sustitutiva. No había evidencia de infección, los coprocultivos fueron negativos y la antitransglutaminasa fue negativa. En ambos casos no había alteraciones macroscópicas y en uno de ellos se realizó biopsia. Se consideró enteropatía asociada a olmesartán, y con su suspensión, la clínica no recurrió. Al ser un efecto secundario reversible de un fármaco común, debemos considerar su suspensión antes de iniciar una investigación exhaustiva de la diarrea crónica.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.